Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
accuracy, Acquiom, Addressing, affirmative, aforesaid, Aghion, Alongside, alter, ALX, anal, Anavex, array, Assumption, Atossa, attachment, aTyr, Baltimore, bankruptcy, bear, Ben, Benjamin, bifurcating, BMI, borne, cancer, capped, Chairperson, Chapter, Chimerix, clawback, COBRA, collateral, contemplated, curve, cybersecurity, de, debtor, default, degenerative, DIP, doubt, downgrade, drafted, drawn, earliest, embedded, Exectuvie, exit, fifteen, Florida, footnote, foreclose, forfeiture, Fulcrum, Genomma, Henry, host, IGG, Immunoglobulin, intelligence, Internacional, irreparable, irrevocable, Island, Jaisim, Ji, JV, lengthy, lent, loan, Lyra, maker, meant, MediciNova, Memorial, Michigan, Minerva, mitigate, Moody, multiplied, nerve, Neuroscience, neurosurgeon, Oncology, outlet, owed, Palestinian, par, peripheral, PeriTech, podcast, popular, preceding, prepayment, proceed, Promissory, prompt, promptly, prospective, Rani, recurring, Relmada, repaid, representation, resale, Rhode, Sackler, scenario, Scilex, Scintilla, segment, Shah, Shapiro, SOFR, Sorrento, spike, spine, stable, subscription, Subtopic, supplementary, surgery, tailored, Technowl, terrorist, thereon, threat, timeframe, transparency, trauma, uncured, unpaid, voided, Voluntary, West, Wire, Zevra
Removed:
abovementioned, accompanied, affiliate, agreeable, alleging, attorney, attribution, authoritative, Aviad, cancelation, cancellation, cancelled, cast, CEO, clarify, clarity, closed, Columbia, computation, concurrent, constrained, continuing, created, CSO, dissent, duration, elapsed, enrolled, epidemic, exclude, excluding, finance, Friedman, fulfilled, geography, globally, heavily, heightened, inapplicable, indexing, Itamar, Kevin, LIBOR, mentioned, modification, outbreak, postpone, putative, Rakin, Raz, regrant, reissued, replacement, sake, Schurr, seventeen, shareholder, specialty, spread, staffing, substitution, suggestion, superseded, Underwriter, vendor, versa, vice
Filing tables
Filing exhibits
- 10-K Annual report
- 10.2 Amendment, Dated April 27, 2023, to Consulting Agreement by and Between Oramed Pharmaceuticals Inc. and Shnida LTD., Entered into As of November 1, 2022, for the Services of Nadav Kidron
- 10.3 Amendment, Dated January 8, 2024, to Consulting Agreement by and Between Oramed Pharmaceuticals Inc. and Shnida LTD., Entered into As of November 1, 2022, for the Services of Nadav Kidron
- 10.5 Amendment, Dated April 27, 2023, to Employment Agreement by and Between Oramed LTD. and Nadav Kidron, Entered into As of November 1, 2022
- 10.6 Amendment, Dated January 8, 2024, to Employment Agreement by and Between Oramed LTD. and Nadav Kidron, Entered into As of November 1, 2022
- 10.15 Amendment, Dated April 27, 2023, to Consulting Agreements by and Between Oramed LTD. and Knry, LTD., Entered into As of July 1, 2008, for the Services of Miriam Kidron
- 10.16 Amendment, Dated January 8, 2024, to Consulting Agreements by and Between Oramed LTD. and Knry, LTD., Entered into As of July 1, 2008, for the Services of Miriam Kidron
- 10.20 Third Amendment, Dated April 27, 2023, to Employment Agreement, by and Between Oramed LTD. and David Silberman
- 10.21 Fourth Amendment, Dated January 8, 2024, to Employment Agreement, by and Between Oramed LTD. and David Silberman
- 10.22 Representative Form of Indemnification Agreements Between Oramed Pharmaceuticals Inc. and Each of Our Directors and Officers
- 23.1 Consent of Kesselman & Kesselman, Independent Registered Public Accounting Firm
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- 32.2 Certification
- 97.1 Oramed Pharmaceuticals Inc. Clawback Policy, Adopted November 9, 2023
- Download Excel data file
- View Excel data file
ORMP similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
In connection with the annual report of Oramed Pharmaceuticals Inc., or the Company, on Form 10-K for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Nadav Kidron, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:
1. | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 6, 2024 | By: | /s/ Nadav Kidron |
Nadav Kidron | ||
President and Chief Executive Officer |